Last reviewed · How we verify
Cyclosporin, low dose steroid
Cyclosporin suppresses T-cell activation and cytokine production, while low-dose steroids provide additional anti-inflammatory effects to reduce immune-mediated tissue damage.
Cyclosporin suppresses T-cell activation and cytokine production, while low-dose steroids provide additional anti-inflammatory effects to reduce immune-mediated tissue damage. Used for Autoimmune or inflammatory conditions requiring immunosuppression (specific indication not publicly detailed for this Phase 3 trial).
At a glance
| Generic name | Cyclosporin, low dose steroid |
|---|---|
| Also known as | Implanta soft capsule |
| Sponsor | Kyungpook National University Hospital |
| Drug class | Calcineurin inhibitor + corticosteroid combination |
| Target | Calcineurin; glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Cyclosporin is a calcineurin inhibitor that blocks T-cell receptor signaling and IL-2 production, preventing T-cell proliferation and activation. The addition of low-dose corticosteroids enhances immunosuppression through glucocorticoid receptor-mediated suppression of inflammatory cytokines and immune cell trafficking. This combination approach aims to achieve therapeutic immunosuppression while minimizing steroid-related toxicity through dose reduction.
Approved indications
- Autoimmune or inflammatory conditions requiring immunosuppression (specific indication not publicly detailed for this Phase 3 trial)
Common side effects
- Nephrotoxicity
- Hypertension
- Hyperglycemia
- Infections
- Tremor
- Gingival hyperplasia
Key clinical trials
- Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy (PHASE3)
- Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation (PHASE4)
- Comparing Everolimus and Sirolimus in Renal Transplant Recipients (NA)
- Phase I/II Thymus Transplantation With Immunosuppression #950 (PHASE1, PHASE2)
- Calcineurin Inhibitor Sparing After Kidney Transplantation (PHASE1, PHASE2)
- Cyclosporine A Plus Low-steroid Treatment in COVID-19 Pneumonia (PHASE1, PHASE2)
- Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy (PHASE4)
- Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclosporin, low dose steroid CI brief — competitive landscape report
- Cyclosporin, low dose steroid updates RSS · CI watch RSS
- Kyungpook National University Hospital portfolio CI